Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine (E.Coli)in Healthy Female Subjects Aged 18 to 25 Years

NCT01356823 is registered in ClinicalTrials.gov with Xiamen University as lead sponsor.

NCT NCT01356823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01356823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine (E.Coli)in Healthy Female Subjects Aged 18 to 25 Years
Lead sponsor
Xiamen University
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2011
Completion date
October 31, 2013
Enrollment
1,600 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, cervical intraepithelial neoplasia